If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

6 Aug 2021 12:15

RNS Number : 8832H
Silence Therapeutics PLC
06 August 2021
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00B9GTXM62

Issuer Name

SILENCE THERAPEUTICS PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

Societe Generale

City of registered office (if applicable)

London

Country of registered office (if applicable)

United Kingdom

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

 

City of registered office (if applicable)

 

Country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reached

30-Jul-2021

6. Date on which Issuer notified

02-Aug-2021

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

5.100000

0.000000

5.100000

4575602

Position of previous notification (if applicable)

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00B9GTXM62

4575602

0

5.100000

0.000000

Sub Total 8.A

4575602

5.100000%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

 

12. Date of Completion

03-Aug-2021

13. Place Of Completion

London, United Kingdom

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLUNAARAUUWRAR
Date   Source Headline
16th Jan 20132:16 pmRNSHolding(s) in Company
14th Jan 20133:08 pmRNSReplacement - Exercise of warrants
14th Jan 20137:00 amRNSExercise of warrants
2nd Jan 20138:36 amRNSAppointment of Chief Medical Officer
31st Dec 201210:30 amRNSHolding(s) in Company
28th Dec 20127:00 amRNSTotal Voting Rights
6th Dec 20124:22 pmRNSHolding(s) in Company
3rd Dec 20123:12 pmRNSOption exercise
3rd Dec 20121:36 pmRNSHolding(s) in Company
3rd Dec 20121:34 pmRNSHolding(s) in Company
30th Nov 201212:52 pmRNSHolding(s) in Company
30th Nov 20128:05 amRNSHolding(s) in Company
30th Nov 20127:00 amRNSOption Exercise and TVR
28th Nov 20128:33 amRNSDirector/PDMR Shareholding
28th Nov 20127:49 amRNSSubscription and Conversion
21st Nov 20127:00 amRNSProposed Placing
5th Nov 201212:52 pmRNSAdviser Change of Name
5th Nov 201210:24 amPRNUS allows two key patents for Silence Therapeutics
19th Oct 20127:00 amPRNExercise of warrants
15th Oct 20127:01 amPRNExercise of warrants
15th Oct 20127:00 amPRNAppointment of finance director
25th Sep 20127:00 amPRNInterim Results for the Six Months Ended 30 June 2012
20th Sep 20122:59 pmPRNNotice of Results
18th Sep 20127:00 amPRNAppointment of Chief Medical Adviser
10th Sep 201211:12 amPRNTR-1: Notification of Major Interest in Shares
10th Sep 20127:00 amPRNSignificant Pre-clinical Data in Acute Lung Injury
4th Sep 201212:19 pmPRNTR-1: Notification of Major Interest in Shares
29th Aug 20124:40 pmRNSSecond Price Monitoring Extn
29th Aug 20124:35 pmRNSPrice Monitoring Extension
24th Aug 20122:41 pmPRNTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
22nd Aug 20127:00 amPRNCollaboration with MiReven Pty Ltd
20th Aug 20122:44 pmPRNTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
10th Aug 201212:20 pmPRNHolding(s) in Company
6th Aug 201212:21 pmPRNTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
3rd Aug 20125:35 pmPRNTR-1: Notification of Major Interest in Shares
2nd Aug 201212:12 pmPRNTR-1: Notification of Major Interest in Shares
2nd Aug 20129:00 amPRNAdmission of shares and Board update
31st Jul 201211:26 amPRNNotice of EGM
31st Jul 20127:00 amPRNResults of Open Offer
30th Jul 20125:35 pmPRNHolding(s) in Company
27th Jul 201212:12 pmPRNTR-1: Notification of Major Interest in Shares
24th Jul 20124:35 pmRNSPrice Monitoring Extension
13th Jul 20122:48 pmPRNReplacement - Subscription and Open Offer
12th Jul 20127:00 amPRNSubscription and Open Offer to Raise up to £5.7 million
10th Jul 201210:34 amPRNResponse to press speculation
22nd Jun 20121:35 pmPRNResult of Annual General Meeting
6th Jun 201212:00 pmPRNPhase I data for Atu027 and Potential Fundraising
17th May 20127:00 amPRNNew data from Phase I trial with Atu027
14th May 20127:00 amPRNPublication of 2011 Annual Report and Notice of AGM
3rd May 20127:00 amPRNSilence Therapeutics’ Partner extends agreement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.